Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of sclerostin in vivo

Molecular Therapy Nucleic Acids

Volumn 5, Issue 9, 2016, Pages e363-

  Basha, Genc ^a   Ordobadi, Mina ^a   Scott, Wilder R ^a   Cottle, Andrew ^a   Liu, Yan ^a   Wang, Haitang ^a   Cullis, Pieter R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

bone formation; lipid nanoparticles; sclerostin; siRNA

Indexed keywords

LIPID; MESSENGER RNA; NANOPARTICLE; SCLEROSTIN; SMALL INTERFERING RNA; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE; GENE DELIVERY SYSTEM; GENE SILENCING; IN VIVO STUDY; MARKER GENE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOST GENE; UPREGULATION;

EID: 84987864167     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.68     Document Type: Article

References (38)

1. Klibanski, A, Adams-Campbell, L, Bassford, T, Blair, SN, Boden, SD, Dickersin, K et al. (2001). Osteoporosis: prevention, diagnosis, and therapy. JAMA 285: 785-795
2. Moon, RT, Bowerman, B, Boutros, M, and Perrimon, N (2002). The promise, and perils of Wnt signaling through beta-catenin. Science 296: 1644-1646
3. Poole, KE, van Bezooijen, RL, Loveridge, N, Hamersma, H, Papapoulos, SE, Löwik, CW et al. (2005). Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19: 1842-1844
4. Brunkow, ME, Gardner, JC, Van Ness, J, Paeper, BW, Kovacevich, BR, Proll, S et al. (2001). Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68: 577-589
5. Winkler, DG, Sutherland, MK, Geoghegan, JC, Yu, C, Hayes, T, Skonier, JE et al. (2003). Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276
6. Hamersma, H, Gardner, J, and Beighton, P (2003). The natural history of sclerosteosis. Clin Genet 63: 192-197
7. Vanhoenacker, FM, Balemans, W, Tan, GJ, Dikkers, FG, De Schepper, AM, Mathysen, DG et al. (2003). Van Buchem disease: lifetime evolution of radioclinical features. Skeletal Radiol 32: 708-718
8. McClung, MR, Grauer, A, Boonen, S, Bolognese, MA, Brown, JP, Diez-Perez, A et al. (2014). Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370: 412-420
9. Saeed, H, Taipaleenmäki, H, Aldahmash, AM, Abdallah, BM, and Kassem, M (2012). Mouse embryonic fibroblasts (MEF) exhibit a similar but not identical phenotype to bone marrow stromal stem cells (BMSC). Stem Cell Rev 8: 318-328
10. Lengner, CJ, Lepper, C, van Wijnen, AJ, Stein, JL, Stein, GS, and Lian, JB (2004). Primary mouse embryonic fibroblasts: a model of mesenchymal cartilage formation. J Cell Physiol 200: 327-333
11. Yan, X, Kuipers, F, Havekes, LM, Havinga, R, Dontje, B, Poelstra, K et al. (2005). The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 328: 57-62
12. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous, and exogenous ligandbased mechanisms. Mol Ther 18: 1357-1364
13. Murphy, AJ, Akhtari, M, Tolani, S, Pagler, T, Bijl, N, Kuo, CL et al. (2011). ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 121: 4138-4149
14. Gan, HT, Tham, M, Hariharan, S, Ramasamy, S, Yu, YH, and Ahmed, S (2011). Identification of ApoE as an autocrine/paracrine factor that stimulates neural stem cell survival via MAPK/ERK signaling pathway. J Neurochem 117: 565-578
15. Haussecker, D (2012). The business of RNAi therapeutics in 2012. Mol Ther Nucleic Acids 1: e8
16. Coelho, T, Adams, D, Silva, A, Lozeron, P, Hawkins, PN, Mant, T et al. (2013). Safety, and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829
17. Fitzgerald, K, Frank-Kamenetsky, M, Shulga-Morskaya, S, Liebow, A, Bettencourt, BR, Sutherland, JE et al. (2014). Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68
18. Wang, Y, and Grainger, DW (2013). Developing siRNA therapies to address osteoporosis. Ther Deliv 4: 1239-1246
19. Zhang, G, Guo, B, Wu, H, Tang, T, Zhang, BT, Zheng, L et al. (2012). A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 18: 307-314
20. Liang, C, Guo, B, Wu, H, Shao, N, Li, D, Liu, J et al. (2015). Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med 21: 288-294
21. Chonn, A, Cullis, PR, and Devine, DV (1991). The role of surface charge in the activation of the classical, and alternative pathways of complement by liposomes. J Immunol 146: 4234-4241
22. Wei, X, Shao, B, He, Z, Ye, T, Luo, M, Sang, Y et al. (2015). Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase, and cause subsequent inflammatory response. Cell Res 25: 237-253
23. Li, X, Ominsky, MS, Warmington, KS, Morony, S, Gong, J, Cao, J et al. (2009). Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588
24. Ominsky, MS, Li, C, Li, X, Tan, HL, Lee, E, Barrero, M et al. (2011). Inhibition of sclerostin by monoclonal antibody enhances bone healing, and improves bone density, and strength of nonfractured bones. J Bone Miner Res 26: 1012-1021
25. Chen, M, Qiao, H, Su, Z, Li, H, Ping, Q, and Zong, L (2014). Emerging therapeutic targets for osteoporosis treatment. Expert Opin Ther Targets 18: 817-831
26. Li, X, Warmington, KS, Niu, QT, Asuncion, FJ, Barrero, M, Grisanti, M et al. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25: 2647-2656
27. Jayaraman, M, Ansell, SM, Mui, BL, Tam, YK, Chen, J, Du, X et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed 51: 8529-8533
28. Basha, G, Novobrantseva, TI, Rosin, N, Tam, YY, Hafez, IM, Wong, MK et al. (2011). Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther 19: 2186-2200
29. Chen, S, Tam, YY, Lin, PJ, Leung, AK, Tam, YK, and Cullis, PR (2014). Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. J Control Release 196: 106-112
30. Mui, BL, Tam, YK, Jayaraman, M, Ansell, SM, Du, X, Tam, YY et al. (2013). Influence of polyethylene glycol lipid desorption rates on pharmacokinetics, and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids 2: e139
31. Cabral, H, Matsumoto, Y, Mizuno, K, Chen, Q, Murakami, M, Kimura, M et al. (2011). Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6: 815-823
32. Huo, S, Ma, H, Huang, K, Liu, J, Wei, T, Jin, S et al. (2013). Superior penetration, and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res 73: 319-330
33. Belliveau, NM, Huft, J, Lin, PJ, Chen, S, Leung, AK, Leaver, TJ et al. (2012). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol Ther Nucleic Acids 1: e37
34. Sahay, G, Querbes, W, Alabi, C, Eltoukhy, A, Sarkar, S, Zurenko, C et al. (2013). Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 31: 653-658
35. Sun, H, Gulbagci, NT, Taneja, R. Cancer Genomics, and Proteomics: Methods, and Protocols. 2007. P. B. Fisher, edn. Humana Press Inc., Totowa, New Jersey, vol. 383, pp. 311-319
36. Rettig, GR, and Behlke, MA (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20: 483-512
37. Varghese, F, Bukhari, AB, Malhotra, R, and De, A (2014). IHC Profiler: an open source plugin for the quantitative evaluation, and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 9: e96801
38. Burgess, A, Vigneron, S, Brioudes, E, Labbé, JC, Lorca, T, and Castro, A (2010). Loss of human Greatwall results in G2 arrest, and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci USA 107: 12564-12569